Clinical trial NCT05065762: Measuring the Treatment Preferences of Participants in Japan With Moderate-to-Severe Psoriasis (PsO) Using Discrete Choice Experiment
Official title: Patient Preference for Treatment of Moderate-To-Severe Psoriasis in Japan
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Psoriasis
Keywords: Psoriasis
Japan
BMS-986165
Observational study
Moderate-to-severe PsO
DCE (discrete choice experiment)
Preferences
Lead sponsor: Bristol-Myers Squibb
Sponsor class: INDUSTRY
First posted: 2021-10-04
Enrollment: 232
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: A total of 10 participants, diagnosed as moderate-to-severe Psoriasis (PsO) by a clinician were included in the Phase 1 qualitative interview

A total of 200 participants, self-reported as moderate-to-severe PsO, were included in the Phase 2 online survey

Brief summary: The purpose of this observational study is to identify and weight the treatment attributes from the moderate-to-severe Psoriasis (PsO) patients' perspective in Japan.


Eligibility criteria: Inclusion Criteria:

* Diagnosis of moderate-to-severe Psoriasis (PsO) by physician (phase 1) or self-reported (phase 2)
* Currently taking systemic psoriasis treatment
* Japanese resident aged 20 years and older

Exclusion Criteria:

* Unable or unwilling to provide informed consent
* Diagnosis of guttate, inverse, pustular, erythrodermic, or drug-induced psoriasis

Primary outcomes:
measure: Psoriasis (PsO) patient preferences of moderate-to-severe systemic treatment atrribute
timeFrame: Within 60 minutes of survey/interview
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 1: Sex
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of PsO participants in Phase 1: Age
timeFrame: At Baseline
measure: Distribution of clinical characteristics of PsO participants in Phase 1: Time since PsO diagnosis
timeFrame: At Baseline
measure: Distribution of clinical characteristics of PsO participants in Phase 1: Severity of PsO
timeFrame: At Baseline
measure: Distribution of clinical characteristics of PsO participants in Phase 1: Current treatments for PsO
timeFrame: At Baseline
measure: Distribution of clinical characteristics of PsO participants in Phase 1: Time on current PsO treatment
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of PsO participants in Phase 1: Residence
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of PsO participants in Phase 1: Employment status
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of PsO participants in Phase 1: Education
timeFrame: At Baseline
measure: Distribution of clinical characteristics of PsO participants in Phase 1: Total number of previous treatments
timeFrame: At Baseline
measure: Distribution of clinical characteristics of PsO participants in Phase 1: Previous treatments for PsO
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of PsO participants in Phase 1: Level of income
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Sex
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Age
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Height
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Weight
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Residence
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Employment status
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Type of occupation
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Education
timeFrame: At Baseline
measure: Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time since PsO diagnosis
timeFrame: At Baseline
measure: Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Self-reported severity
timeFrame: At Baseline
measure: Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Current treatments for PsO
timeFrame: At Baseline
measure: Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Time on current PsO treatment
timeFrame: At Baseline
measure: Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Previous treatments for PsO
timeFrame: At Baseline
measure: Distribution of clinical characteristics of Psoriasis (PsO) participants in Phase 2: Comorbid conditions of interest
timeFrame: At Baseline
measure: Distribution of socio-demographic characteristics of Psoriasis (PsO) participants in Phase 2: Level of income
timeFrame: At Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Morrisville
country: United States
facility: Local Institution
state: North Carolina
Study officials:
affiliation: Bristol-Myers Squibb
name: Bristol-Myers Squibb
role: STUDY_DIRECTOR
References: